FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention relates to a crystalline form of a bisulfate JAK-kinase inhibitor. Crystalline form II of bisulphate (3aR,5s,6aS)-N-(3-methoxyl-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)hexahydro-cyclopenta[c]pyrrol-2(1H)-formamide has X-ray powder diffraction spectrum, which is obtained by using Cu-Kα radiation and is represented by angle 2θ and interplanar distance, where characteristic peaks are given at approximately 8.96 (9.87); 11.80 (7.50); 13.12 (6.74); 13.53 (6.54); 13.89 (6.37); 14.42 (6.14); 14.98 (5.91); 16.52 (5.36); 18.20 (4.87); 18.75 (4.73); 19.15 (4.63); 19.72 (4.50); 20.82 (4.26); 22.05 (4.03); 22.52 (3.95); 22.92 (3.88); 23.58 (3.77) and 27.04 (3.30). Crystalline form II is intended for preparing a pharmaceutical composition for preparing a drug for treating a JAK-related disease, which is rheumatic and rheumatoid arthritis.
EFFECT: invention discloses a crystalline form of a bisulfate JAK-kinase inhibitor and a method for production thereof.
5 cl, 4 dwg, 2 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CRYSTALLINE FORM OF INHIBITOR BISULPHATE JAK AND METHOD FOR PRODUCTION THEREOF | 2015 |
|
RU2704795C2 |
| BISULFATE OF JANUS KINAZE (JAK) INHIBITOR AND METHOD FOR ITS PREPARATION | 2014 |
|
RU2665680C2 |
| DERIVATIVES OF PYRROLOPYRIMIDINE USEFUL AS JAK-KINASES INHIBITORS | 2012 |
|
RU2618673C2 |
| PHARMACEUTICAL COMPOSITION INCLUDING JANUS KINASE INHIBITOR OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 2017 |
|
RU2744432C2 |
| RMT5 INHIBITORS | 2019 |
|
RU2814198C2 |
| CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DESTRUCTION OF ANDROGEN RECEPTORS AND USE THEREOF | 2020 |
|
RU2825000C2 |
| SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | 2011 |
|
RU2606514C2 |
| SUBSTITUTED CARBONUCLEOSIDES DERIVATIVES USED AS ANTICANCER AGENTS | 2017 |
|
RU2712944C1 |
| PYRAZOLE-BASED MAGL INHIBITORS | 2018 |
|
RU2789157C2 |
| BICYCLIC AMINES AS NEW INHIBITORS OF JAK KINASE | 2018 |
|
RU2764980C2 |
